NASDAQ · LPCN
Healthcare · Biotechnology
$2.11
Up+$0.05 (+2.43%)
Updated Aug 15, 2026, 3:09 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
LPCN closed at $2.11 after 21 trading sessions, down 5.38% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $2.10 | $2.18 | $2.07 | $2.11 | 31.39K |
| Aug 13, 2026 | $2.07 | $2.2237 | $2.04 | $2.06 | 23.73K |
| Aug 12, 2026 | $2.11 | $2.13 | $2.02 | $2.06 | 48.97K |
| Aug 11, 2026 | $2.10 | $2.1599 | $2.09 | $2.09 | 13.32K |
| Aug 10, 2026 | $2.16 | $2.21 | $2.10 | $2.10 | 41.49K |
| Aug 7, 2026 | $2.26 | $2.26 | $2.12 | $2.13 | 33.86K |
| Aug 6, 2026 | $2.14 | $2.18 | $2.08 | $2.13 | 37.01K |
| Aug 5, 2026 | $2.19 | $2.2605 | $2.15 | $2.17 | 56.2K |
| Aug 4, 2026 | $2.13 | $2.2199 | $2.06 | $2.13 | 131.36K |
| Aug 3, 2026 | $2.239 | $2.239 | $2.03 | $2.11 | 91.27K |
| Jul 31, 2026 | $2.16 | $2.16 | $2.10 | $2.12 | 29.43K |
| Jul 30, 2026 | $2.05 | $2.1999 | $2.05 | $2.11 | 58.35K |
| Jul 29, 2026 | $2.13 | $2.1499 | $2.06 | $2.07 | 38.27K |
| Jul 28, 2026 | $2.27 | $2.27 | $2.12 | $2.14 | 32.07K |
| Jul 27, 2026 | $2.09 | $2.16 | $2.09 | $2.14 | 29.43K |
| Jul 24, 2026 | $2.23 | $2.23 | $2.08 | $2.08 | 35.75K |
| Jul 23, 2026 | $2.20 | $2.22 | $2.17 | $2.19 | 22.04K |
| Jul 22, 2026 | $2.232 | $2.25 | $2.18 | $2.23 | 30.91K |
| Jul 21, 2026 | $2.15 | $2.2541 | $2.15 | $2.19 | 17.1K |
| Jul 20, 2026 | $2.24 | $2.24 | $2.15 | $2.15 | 31.39K |
| Jul 17, 2026 | $2.27 | $2.29 | $2.23 | $2.23 | 20.67K |
The latest Smart Investors Daily articles mentioning LPCN.
LPCN research
Company profile and research snapshot.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 6, 2026 | HC Wainwright & Co. | Neutral | — |
| Jan 21, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 13, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 20, 2025 | HC Wainwright & Co. | Buy | — |
| Jun 27, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Aug 4, 2026
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the second quarter ended June 30, 2026 and provided a corporate update.
Benzinga · Aug 4, 2026
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.43) by 25.58 percent. This is a 21.95 percent increase over losses of $(0.41) per share from the
Yahoo · Aug 3, 2026
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the appointment of Michael J. Grissinger to its Board of Directors, effective August 3, 2026.
Benzinga · Feb 26, 2026
-SEC Filing
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LPCN.
